Geron (Nasdaq: GERN) granted stock options as inducement awards to eight new employees, effective June 17, 2026. The options cover an aggregate 690,000 shares of common stock at an exercise price of $1.23 per share, matching the closing price on the grant date.
The options have a 10-year term and vest over four years: 12.5% on the six-month employment anniversary and the remainder in equal monthly installments over 42 months, subject to continued employment. The awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and Geron’s 2018 Inducement Award Plan.
On the day this news was published, GERN gained 6.35%, reflecting a notable positive market reaction.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This price movement added approximately $50M to the company's valuation, bringing the market cap to $837.18M at that time.
The stock moved +6.3% in the session following this news. A strong positive reaction aligns with pre...
Analysis
The stock moved +6.3% in the session following this news. A strong positive reaction aligns with pre-existing upward momentum and could reflect confidence in Geron’s hiring and equity incentives, though moderately elevated short interest and broader biotech volatility remain potential sources of reversal risk.
Key Figures
Inducement option shares:690,000 sharesNew employees:8 employeesOption exercise price:$1.23 per share+5 more
8 metrics
Inducement option shares690,000 sharesAggregate stock options granted to eight new employees
New employees8 employeesRecipients of inducement stock option grants
Option exercise price$1.23 per shareEqual to GERN closing price on June 17, 2026 grant date
Option term10 yearsDuration of inducement stock options
Vesting period4 yearsTotal vesting duration for inducement options
Initial vesting tranche12.5%Portion vesting at six-month employment anniversary
Remaining vesting42 monthsEqual monthly installments after initial six-month vest
Pre-news share price$1.23Price before this announcement; within 52-week range of $1.04–$2.01
Planned management presentations at major May 2026 investor healthcare conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news reactions are mixed, with slightly more instances of divergence between news tone and share-price move.
Regulatory & Risk Context
Short Interest: 11.76%
Short Interest
11.76% of float
0%15%30%+
moderateas of 2026-05-29Days to cover: 7.61
Short positioning is moderately elevated, suggesting potential for sharper price swings and the possibility of short-covering to amplify moves around catalysts.
Key Terms
nasdaq listing rule 5635(c)(4), exercise price, stock options, inducement award plan
4 terms
nasdaq listing rule 5635(c)(4)regulatory
"granted by the Compensation Committee ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"The stock options have an exercise price of $1.23 per share, which is equal"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
stock optionsfinancial
"it granted stock options to purchase an aggregate of 690,000 shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
inducement award planregulatory
"subject to the terms and conditions of Geron’s 2018 Inducement Award Plan"
An inducement award plan is a package of pay, often including stock options or restricted shares, granted to a new employee or executive to attract them to join a company — think of it like a signing bonus paid partly in company stock. Investors care because these awards increase compensation expense and can dilute existing shareholders’ ownership, affecting earnings per share and incentives that shape company strategy.
FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
The stock options have an exercise price of $1.23 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.
About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
CONTACT: Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com
FAQ
What stock options did Geron (GERN) grant on June 17, 2026?
Geron granted stock options for 690,000 common shares to eight newly hired employees. According to Geron, these inducement awards were effective June 17, 2026 and were intended as material incentives for the employees’ acceptance of employment with the company.
What is the exercise price of the new Geron (GERN) inducement stock options?
The new Geron inducement options have an exercise price of $1.23 per share. According to Geron, this price equals the closing price of Geron’s common stock on the June 17, 2026 grant date, aligning option value with the market at issuance.
How do the Geron (GERN) inducement stock options vest for new employees?
The Geron inducement options vest over four years, starting six months after employment begins. According to Geron, 12.5% vests at the six-month anniversary, with the remaining shares vesting in equal monthly installments over the next 42 months, subject to continued employment.
Why did Geron (GERN) use Nasdaq Listing Rule 5635(c)(4) for these stock option grants?
Geron used Nasdaq Listing Rule 5635(c)(4) to grant options as inducement awards for new hires. According to Geron, the Compensation Committee approved these equity awards under this rule and the company’s 2018 Inducement Award Plan and stock option agreement form.
How many employees received Geron (GERN) inducement stock options and under which plan?
Eight newly hired employees received Geron inducement stock options covering 690,000 shares in total. According to Geron, these options were granted under the company’s 2018 Inducement Award Plan and are governed by its standard stock option agreement form.
What is the term length of the Geron (GERN) inducement stock options granted in June 2026?
The Geron inducement stock options granted in June 2026 have a 10-year term. According to Geron, these options may be exercised during this period, subject to their vesting schedule and the employees’ continued employment through the applicable vesting dates.
